Andrew Pask

Colossal Targets Extinct Antelope—and Adds a New Branch to its De-Extinction ‘Tree of Life’

by | Apr 30, 2026
At a $10 billion valuation—and spinning out new ventures—Colossal names the bluebuck its sixth de-extinction target, extending its biotech platform into antelope conservation through a global BioVault effort.
MORE
Colossal Biosciences Names Australian De‑Extinction Scientist as Its Chief Biology Officer
by | Aug 20, 2025
Andrew Pask is known for his expertise in de-extinction science, developmental genetics, and conservation technologies. He leads the Thylacine Integrated Genomic Restoration Research Lab (TIGGR) at the University of Melbourne in Australia.
MORE